AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17036484
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral hypoglycemic drug)
Trial: 14743961
Drug: Pravastatin 80
RxNorm normalized name: pravastatin 80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 80 mg/day for 8 weeks
Trial: 10719694
Drug: Conventional Treatment
RxNorm normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Treatment Position (CTP)
Trial: 8732493
Drug: Hyperinsulinaemic, euglycaemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinaemic, euglycaemic clamp (1 mu kg‐1 min‐1, 5 mmol L‐1)
Trial: 7904767
Drug: Sodium chromoglycate
RxNorm normalized name: cromoglycate
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chromoglycate 10 mg q.i.d. for 4 weeks (control)
Trial: 27440671
Drug: rhBMP-2/ACS (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhBMP-2/ACS (1.5 mg/ml; total dose 4.2 mg)
Trial: 10687882
Drug: E2 Matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 Matrix 0.10 mg
Trial: 10687882
Drug: E2 Matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 Matrix 0.05 mg
Trial: 8440761
Drug: Ethanol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (25 mL in 150 mL of grapefruit juice)
Trial: 3532535
Drug: Adjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormonal therapy with diethylstilbestrol
Trial: 3532535
Drug: Adjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormonal therapy with tamoxifen
Trial: 25380842
Drug: Endoscopic sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic sequential treatment (Group A: local chemotherapeutic drug injection with ordinary metal stent implantation)
Trial: 25380842
Drug: Endoscopic sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic sequential treatment (Group B: local chemotherapeutic drug injection with iodine‐125 particle implantation)
Trial: 25380842
Drug: Endoscopic sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic sequential treatment (Group C: radiofrequency therapy with ordinary metal stent)
Trial: 25380842
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (Group D: local chemotherapeutic drug injection)
Trial: 25380842
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (Group E: RF therapy)
Trial: 25380842
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (Group F: common metal stent implantation)
Trial: 22008715
Drug: Implants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants with SLA surface
Trial: 15784070
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nicotine and smoking-related stimuli
Trial: 8687199
Drug: Lazabemide 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazabemide 25 mg/day
Trial: 8687199
Drug: Lazabemide 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazabemide 50 mg/day
Trial: 12359039
Drug: Lazabemide 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazabemide 100 mg/day
Trial: 12359039
Drug: Lazabemide 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazabemide 200 mg/day
Trial: 1531994
Drug: Budesonide, 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide, 1.6 mg daily for 3 weeks
Trial: 1531994
Drug: Prednisone, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone, 40 mg daily for 8 days
Trial: 4072589
Drug: N2O, oxygen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N2O, oxygen, and halogenated agents
Trial: 31623675
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin C supplementation (500 mg daily during the last 2 cycles)
Trial: 24362951
Drug: Everolimus (EVE)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (EVE) + Exemestane (EXE) (10 mg/day + 25 mg/day)
Trial: 24362951
Drug: Placebo (PBO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PBO) + Exemestane (EXE) (placebo + 25 mg/day)
Trial: 20211040
Drug: Maternal multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal multivitamin supplements
Trial: 12356611
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine combined with interferon alfa
Trial: 8540719
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg daily for 6 days)
Trial: 8540719
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg every 8 h for 5 days plus omeprazole)
Trial: 31669837
Drug: Saffron (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron (60 mg/day)
Trial: 25765348
Drug: 5% minoxidil
RxNorm normalized name: MINOXIDIL 5 g in 100 mL TOPICAL LIQUID [ASDTOTIO 5% minoxidil]
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5% minoxidil topical foam (5% MTF)
Trial: 26387973
Drug: Placebo topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo topical foam (plaTF) until week 24, followed by 5% MTF until week 104
Trial: 23052313
Drug: Trimethoprim-sulfamethoxazole (SXT)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (SXT) on Mueller-Hinton agar (MHA) with defibrinated horse blood and 20 mg/liter β‐NAD (MHF)
Trial: 10193219
Drug: Cisatracurium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.1 mg.kg‐1
Trial: 9797517
Drug: Cisatracurium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.15 mg.kg‐1
Trial: 9797517
Drug: Cisatracurium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.1 mg.kg‐1 with spontaneous recovery
Trial: 9797517
Drug: Cisatracurium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.1 mg.kg‐1 with neostigmine at 10% recovery
Trial: 9797517
Drug: Cisatracurium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.1 mg.kg‐1 with neostigmine at 25% recovery
Trial: 9797517
Drug: Cisatracurium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.15 mg.kg‐1 with spontaneous recovery
Trial: 9797517
Drug: Cisatracurium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.15 mg.kg‐1 with neostigmine at 10% recovery
Trial: 9797517
Drug: Cisatracurium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.15 mg.kg‐1 with neostigmine at 25% recovery
Trial: 9797517
Drug: Atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.5 mg.kg‐1 with spontaneous recovery
Trial: 9797517
Drug: Atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.5 mg.kg‐1 with neostigmine at 10% recovery
Trial: 9797517
Drug: Atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.5 mg.kg‐1 with neostigmine at 25% recovery
Trial: 241599
Drug: Alclofenac 1
RxNorm normalized name: Acéclofénac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alclofenac 1 g t.d.s.
Trial: 17114560
Drug: Midazolam syrup
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam syrup (0.5 mg/kg)
Trial: 9235377
Drug: Ozone-containing solutions
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone-containing solutions
Trial: 8234438
Drug: Bulk laxative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bulk laxative plus senna (Agiolax) daily doses 14.8 g
Trial: 8234438
Drug: Lactulose (Levolac)
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose (Levolac) daily doses 20.1 g
Trial: 3303178
Drug: 1% mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% mepivacaine (40 ml)
Trial: 3303178
Drug: 1% prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% prilocaine (40 ml)
Trial: 23559323
Drug: Postoperative systemic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative systemic steroids (100 mg prednisolone per day for 5 days)
Trial: 15572391
Drug: Knee pain
RxNorm normalized name: Tenscare Kneestim For Knee Pain And Arthritis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knee pain induced by injection of hypertonic saline into the infrapatellar fat pad
Trial: 8862101
Drug: Simvastatin, 20
RxNorm normalized name: Simvastatin, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin, 20 to 40 mg once daily
Trial: 6131914
Drug: anti-H1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-H1 plus anti-H2 (cimetidine, 300 mg t.i.d.)
Trial: 28449710
Drug: 6% hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydroxyethyl starch (HES) 130/0.4, 20 mL·kg‐1
Trial: 28449710
Drug: 5% Human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Human Albumin (HA), 20 mL·kg‐1
Trial: 23765203
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of dietary MSG and aspartame (n = 36)
Trial: 12585189
Drug: Tongxinluo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongxinluo capsule (TXLC)
Trial: 2148882
Drug: Subcutaneous bolus
RxNorm normalized name: subcutaneous bolus insulin patch pump, 200 unit, disposable 2 unit MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous bolus injection of GM-CSF (0.3-30 micrograms/kg)
Trial: 2148882
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus injection of GM-CSF (0.3-30 micrograms/kg)
Trial: 2148882
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of GM-CSF (0.3-30 micrograms/kg)
Trial: 2148882
Drug: All methods
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All methods of administration (subcutaneous bolus, intravenous bolus, intravenous infusion)
Trial: 2148882
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of GM-CSF at doses below 3 micrograms/kg
Trial: 2148882
Drug: All methods
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All methods of administration
Trial: 106264
Drug: 3 X
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 X 50 mg bezafibrate daily
Trial: 106264
Drug: 3 X
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 X 100 mg bezafibrate daily
Trial: 106264
Drug: 3 X
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 X 150 mg bezafibrate daily
Trial: 106264
Drug: 3 X
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 X 200 mg bezafibrate daily
Trial: 106264
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg bezafibrate daily (optimal dose)
Trial: 30563932
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg daily for 3 days, then twice daily for 1 to 5 weeks)
Trial: 19479614
Drug: Involved field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved field radiotherapy (RT) after induction chemotherapy (CT)
Trial: 12577415
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) alone
Trial: 11485506
Drug: Alosetron hydrochloride
RxNorm normalized name: Alosetron Hydrochloride
DrugBank: Alosetron (DB00969)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alosetron hydrochloride 1 mg twice daily for 12 weeks
Trial: 2692178
Drug: Oral salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral salbutamol 4 mg t.d.s.
Trial: 2692178
Drug: Intravenous salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous salbutamol infused until maternal heart rate rose above 100 bpm for 30 mins
Trial: 27889661
Drug: Screening with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening with PSA threshold of 3 ng/ml
Trial: 27889661
Drug: Screening with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening with PSA threshold of 4 ng/ml
Trial: 26272447
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy with lavender oil (2 consecutive cycles of effleurage massage)
Trial: 24156091
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement taken each dialysis session (drink or pudding style)
Trial: 22205554
Drug: MCT/LCT fat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT/LCT fat infusion
Trial: 22205554
Drug: Fish oil‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil‐based (ω‐3) fat infusion
Trial: 16918949
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment (1.3, 2.0 and 2.7 mg/m2/day)
Trial: 16918949
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment (2.7 mg/m2/day)
Trial: 12950901
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg twice a day for 2 days (days 1 and 2)
Trial: 12950901
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg twice a day for 8 days (days 1 and 8)
Trial: 12950901
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg single dose (day 1)
Trial: 10872186
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (children without rhGH treatment)
Trial: 9166391
Drug: Ipriflavone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipriflavone (200 mg t.i.d)
Trial: 4074623
Drug: +sotalol (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +sotalol (0.125 mg kg‐1 to 2.0 mg kg‐1)
Trial: 21969017
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (control)
Trial: 23865441
Drug: LOS +
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LOS + HCTZ (50 mg/day losartan + 12.5 mg/day hydrochlorothiazide)
Trial: 23865441
Drug: TEL +
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TEL + HCTZ (40 mg/day telmisartan + 12.5 mg/day hydrochlorothiazide)
Trial: 7846193
Drug: Imipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (mean dose 75 mg daily) plus mianserin (mean dose 25 mg daily)
Trial: 7846193
Drug: Desipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (mean dose 66 mg daily) plus mianserin (mean dose 27 mg daily)
Trial: 31172644
Drug: Mifepristone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (200 mg oral administration)
Trial: 29103416
Drug: Phlai capsules
RxNorm normalized name: Mycobacterium phlei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phlai capsules 100 mg
Trial: 29103416
Drug: Phlai capsules
RxNorm normalized name: Mycobacterium phlei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phlai capsules 200 mg
Trial: 25882986
Drug: Pazopanib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib plus weekly paclitaxel (800 mg daily + 80 mg/m² weekly)
Trial: 25882986
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel alone (80 mg/m² weekly)
Trial: 25882986
Drug: Pazopanib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib plus weekly paclitaxel
Trial: 22813409
Drug: Oral cholecalciferol
RxNorm normalized name: cholecalciferol Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholecalciferol (60,000 units/week) and calcium carbonate (1g/day) along with anti-tubercular treatment (ATT)
Trial: 16395307
Drug: Naltrexone 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 25 mg pretreatment with lower subperceptual ketamine dose (0.081 mg/kg bolus, 0.4 mg/kg/h infusion)
Trial: 16395307
Drug: Higher perception-altering
RxNorm normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Higher perception-altering ketamine dose (0.23 mg/kg bolus, 0.58 mg/kg infusion)
Trial: 16395307
Drug: Lower subperceptual
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower subperceptual ketamine dose
Trial: 16395307
Drug: Higher ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher ketamine dose
Trial: 19222770
Drug: Preoperative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative and postoperative local anesthetic mixture (10 mL 2% lidocaine added to 10 mL 0.5% bupivacaine)
Trial: 19222770
Drug: Preoperative saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative saline and postoperative local anesthetic mixture (10 mL 2% lidocaine added to 10 mL 0.5% bupivacaine)
Trial: 16508385
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 4 days before surgery and oral rofecoxib 50 mg on the morning of surgery
Trial: 16508385
Drug: Oral rofecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rofecoxib 50 mg for 4 days before surgery and the morning of surgery
Trial: 11524352
Drug: 0.5% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% levobupivacaine (15 mL, 75 mg)
Trial: 9236446
Drug: Vehicle (air)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (air) inhalation
Trial: 8103703
Drug: Cetirizine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (15 mg twice daily for 1 week)
Trial: 8103703
Drug: Placebo (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (after single dose PAF challenge)
Trial: 8103703
Drug: Placebo (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (after 1 week treatment)
Trial: 3092699
Drug: 0.15‐0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15‐0.2 mg/kg nalbuphine
Trial: 3092699
Drug: 0.75‐1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75‐1.0 mg/kg tramadol
Trial: 8679352
Drug: Remifentanil low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil low dose (1 microgram kg‐1 i.v. over 1 min and an infusion of 0.2 microgram kg‐1 min‐1)
Trial: 8679352
Drug: Remifentanil medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil medium dose (2.5 micrograms kg‐1 and 0.5 microgram kg‐1 min‐1)
Trial: 8679352
Drug: Remifentanil high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil high dose (5 micrograms kg‐1 and 1 microgram kg‐1 min‐1)
Trial: 12635062
Drug: Remifentanil (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (all doses)
Trial: 2056600
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (75 mg.) BCG regimen
Trial: 6192650
Drug: H1 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 and H2 receptor antagonists (used separately and in combination)
Trial: 6192650
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of H1 plus H2 antagonist
Trial: 29149805
Drug: H2 receptor
RxNorm normalized name: Histamine H2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 receptor antagonists
Trial: 6192650
Drug: Potent H1
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potent H1 blocker alone
Trial: 29715698
Drug: ETX +
RxNorm normalized name: Polygonatum biflorum root etxract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETX + 1,25‐(OH) 2 D 3 (1 ng/mL)